Compare Cytokinetics Inc (CYTK) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs SoundHound AI Inc — how do they compare? Cytokinetics Inc trades at $62.77 (market cap $8.62B), while SoundHound AI Inc trades at $5.4 (market cap $2.45B). The key difference: Cytokinetics Inc is far larger — about 3.5× SoundHound AI Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and SoundHound AI Inc for 23 Days on average.
| CYTK | SOUN | |
|---|---|---|
Market Cap | $8.62B | $2.45B |
Volume | 2,594,626 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $87.26 | $21.40 |
52-Week Low | $54.76 | $5.52 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $8.72B | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
SoundHound AI (SOUN) trades at $5.49, down 2.49% today, with bearish technical signals but strong analyst support. The company shows robust revenue growth with 2025 revenue of $168.92M and 2026 projected at $203M, though it remains unprofitable with a -67.45% net margin. Recent developments include expansion in restaurant and banking sectors with voice AI technology, while technical indicators show oversold conditions with RSI at 25-29.
The outlook remains speculative with significant execution risk despite 75% analyst buy ratings and a $9.33 consensus target. Key opportunities include voice AI market expansion and enterprise contract wins, while risks center on persistent losses, high valuation multiples, and competitive pressures in the AI sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
